DUBLIN – Carisma Therapeutics Inc., plans to kickstart a new era in immuno-oncology shortly by testing the first cell therapy to employ macrophages that express a chimeric antigen receptor (CAR). Its lead program, CT-0508, comprises patients' own macrophages engineered to express HER2. It is being readied for patients with HER2-expressing cancers, such as breast, ovarian, lung, gastroesophageal and salivary-gland cancers.